
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$5.05
−$0.10 · -1.94%
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Previous close
$5.05
−$0.10 · -1.94%
Regular session · ET · Market data may be delayed.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Day range
Current $5.05
52-week range
Current $5.05
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
54
Fair Value
Sentiment
51
Mixed
Risk
76
High Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Day range
Current $5.05
52-week range
Current $5.05
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 742.9M USD | 1.04B USD | 1.05B USD | 1.12B USD | 1.77B USD |
| Cost of goods sold | 392.3M USD | 668.2M USD | 689.3M USD | 644.5M USD | 980.4M USD |
| Gross profit | 350.6M USD | 375.4M USD | 360M USD | 473M USD | 793.2M USD |
| Research and development | 53.8M USD | 70.7M USD | 111.4M USD | 188.3M USD | 235.2M USD |
| Selling, general, and administrative | 186.6M USD | 298.7M USD | 356.7M USD | 339.5M USD | 348.7M USD |
| Operating expenses | 240.4M USD | 484.1M USD | 1.09B USD | 643M USD | 451.8M USD |
| Interest expense | 59.3M USD | 71M USD | 87.9M USD | 37.3M USD | 34.5M USD |
| Depreciation and amortization | 95.8M USD | 108.8M USD | 125.1M USD | 143.3M USD | 123.8M USD |
| Operating income | 110.2M USD | −108.7M USD | −726.4M USD | −170M USD | 341.4M USD |
| Net income | 52.6M USD | −190.6M USD | −760.5M USD | −211.6M USD | 219.5M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.00
98.02% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ42.72M3.34%1.2B USD0.48%$32.48-3.39%
Avantis U.S. Small Cap Value ETFAVUV16.15M0.05%30.51B USD0.25%$114.4-1.82%
State Street SPDR S&P Biotech ETFXBI8.53M0.09%9.64B USD0.35%$140.18-2.73%
Vanguard Morningstar Total Stock Market ETFVTI8.3M0.00%689.3B USD0.03%$340.02-3.52%
iShares Russell 2000 ETFIWM7.19M0.01%71.54B USD0.19%$256.61-2.88%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV4.41M0.02%25.71B USD0.31%$36.63-2.01%
Vanguard Extended Market ETFVXF3.82M0.00%30.2B USD0.05%$211.44-3.21%
Dimensional - US Targeted Value ETFDFAT2.97M0.01%29.57B USD0.31%$65.61-1.74%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ
Avantis U.S. Small Cap Value ETFAVUV
State Street SPDR S&P Biotech ETFXBI
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
Vanguard Extended Market ETFVXF
Dimensional - US Targeted Value ETFDFATAI-generated and delayed market data for informational and educational purposes only. Not investment advice.